SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-279578"
 

Search: onr:"swepub:oai:DiVA.org:uu-279578" > Hematopoietic Cell ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Pasquini, Marcelo C.Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • Elsevier BV,2016
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-279578
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-279578URI
  • https://doi.org/10.1016/j.bbmt.2015.08.024DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:132888449URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+AML was associated with higher disease relapse (hazard ratio, 1.98; P < .01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P = .90), and worse survival (hazard ratio, 1.67; P < .01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P < .01), higher TRM (hazard ratio, 1.80; P < .01), and worse survival (HR, 2.02; P < .01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P < .01) and MDS (hazard ratio, 1.79; P < .01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Zhang, Mei-JieMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. (author)
  • Medeiros, Bruno C.Stanford Univ, Sch Med, Dept Hematol, Stanford, CA 94305 USA. (author)
  • Armand, PhilippeDana Farber Canc Inst, Dept Med Oncol Hematol Malignancies, Boston, MA 02115 USA. (author)
  • Hui, Zhen-HuanMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Nishihori, TaigaH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. (author)
  • Aljurf, Mahmoud D.King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh 11211, Saudi Arabia. (author)
  • Akpek, GoerguenBanner MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy Program, Gilbert, AZ USA. (author)
  • Cahn, Jean-YvesUniv Hosp, Dept Hematol, Grenoble, France. (author)
  • Cairo, Mitchell S.New York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, Valhalla, NY 10595 USA. (author)
  • Cerny, JanUMass Mem Med Ctr, Dept Med, Worcester, MA USA. (author)
  • Copelan, Edward A.Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA. (author)
  • Deol, AbhinavWayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA. (author)
  • Freytes, Cesar O.S Texas Vet Hlth Care Syst, Div Hematol & Oncol, San Antonio, TX USA.;Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. (author)
  • Gale, Robert PeterUniv London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. (author)
  • Ganguly, SiddharthaUniv Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA. (author)
  • George, BijuChristian Med Coll & Hosp, Dept Haematol, Vellore, Tamil Nadu, India. (author)
  • Gupta, VikasUniv Hlth Network, Princess Margaret Canc Ctr, Blood & Marrow Transplant Program, Toronto, ON, Canada. (author)
  • Hale, Gregory A.Univ S Florida, All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL 33701 USA. (author)
  • Kamble, Rammurti T.Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA. (author)
  • Klumpp, Thomas R.Thomas Jefferson Univ Hosp, Dept Med Oncol, Philadelphia, PA 19107 USA. (author)
  • Lazarus, Hillard M.Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. (author)
  • Luger, Selina M.Univ Penn, Med Ctr, Abramson Canc Ctr, Dept Med, Philadelphia, PA 19104 USA. (author)
  • Liesveld, Jane L.Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA. (author)
  • Litzow, Mark R.Mayo Clin, Div Hematol & Transplant Ctr, Rochester, MN USA. (author)
  • Marks, David I.Univ Hosp Bristol NHS Trust, Pediat Bone Marrow Transplant, Bristol, Avon, England. (author)
  • Martino, RodrigoHosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain. (author)
  • Norkin, MaximUniv Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA. (author)
  • Olsson, Richard F.Karolinska Institutet,Uppsala universitet,Hematologi,Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden.(Swepub:uu)riols677 (author)
  • Oran, BetulUniv Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA. (author)
  • Pawarode, AttapholUniv Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. (author)
  • Pulsipher, Michael A.Univ So Calif, Keck Sch Med, Childrens Hosp Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA. (author)
  • Ramanathan, MuthalaguUMass Mem Med Ctr, Dept Med, Worcester, MA USA. (author)
  • Reshef, RanUniv Penn, Med Ctr, Abramson Canc Ctr, Dept Med, Philadelphia, PA 19104 USA. (author)
  • Saad, Ayman A.Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. (author)
  • Saber, WaelMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Savani, Bipin N.Vanderbilt Univ, Dept Med, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA. (author)
  • Schouten, Harry C.Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands. (author)
  • Ringden, OlleKarolinska Institutet (author)
  • Tallman, Martin S.Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA. (author)
  • Uy, Geoffrey L.Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. (author)
  • Wood, William A., Jr.Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA. (author)
  • Wirk, BaldeepSeattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA. (author)
  • Perez, Waleska S.Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Batiwalla, MinooNHLBI, NIH, Hematol Branch, Bldg 10, Bethesda, MD 20892 USA. (author)
  • Weisdorf, Daniel J.Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA. (author)
  • Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. (creator_code:org_t)

Related titles

  • In:Biology of blood and marrow transplantation: Elsevier BV22:2, s. 248-2571083-87911523-6536

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view